Deutsche Bank’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-45,651
| Closed | -$275K | – | 5164 |
|
|
2019
Q4 | $275K | Sell |
45,651
-133,623
| -75% | -$773K | ﹤0.01% | 3042 |
|
|
2019
Q3 | $644K | Sell |
179,274
-55,175
| -24% | -$213K | ﹤0.01% | 2559 |
|
|
2019
Q2 | $626K | Sell |
234,449
-264,971
| -53% | -$782K | ﹤0.01% | 3132 |
|
|
2019
Q1 | $1.48M | Buy |
499,420
+232,489
| +87% | +$571K | ﹤0.01% | 2715 |
|
|
2018
Q4 | $423K | Sell |
266,931
-554,932
| -68% | -$1.57M | ﹤0.01% | 3447 |
|
|
2018
Q3 | $3.02M | Sell |
821,863
-1,199,474
| -59% | -$3.57M | ﹤0.01% | 2579 |
|
|
2018
Q2 | $5.72M | Buy |
2,021,337
+136,102
| +7% | +$464K | ﹤0.01% | 2201 |
|
|
2018
Q1 | $6.99M | Sell |
1,885,235
-680,783
| -27% | -$2.23M | ﹤0.01% | 1935 |
|
|
2017
Q4 | $7.39M | Buy |
2,566,018
+900,859
| +54% | +$3.27M | ﹤0.01% | 1717 |
|
|
2017
Q3 | $7.47M | Buy |
1,665,159
+359,259
| +28% | +$1.6M | 0.01% | 1650 |
|
|
2017
Q2 | $5.99M | Sell |
1,305,900
-145,793
| -10% | -$586K | ﹤0.01% | 1784 |
|
|
2017
Q1 | $6.11M | Sell |
1,451,693
-339,629
| -19% | -$1.41M | ﹤0.01% | 1560 |
|
|
2016
Q4 | $7.4M | Buy |
1,791,322
+26,047
| +1% | +$138K | 0.01% | 1443 |
|
|
2016
Q3 | $14.3M | Buy |
1,765,275
+277,652
| +19% | +$2.36M | 0.01% | 1077 |
|
|
2016
Q2 | $11.6M | Buy |
1,487,623
+120,769
| +9% | +$1.04M | 0.01% | 1212 |
|
|
2016
Q1 | $10.6M | Sell |
1,366,854
-49,973
| -4% | -$366K | 0.01% | 1226 |
|
|
2015
Q4 | $15.3M | Buy |
1,416,827
+709,723
| +100% | +$6.45M | 0.01% | 1072 |
|
|
2015
Q3 | $4.88M | Buy |
707,104
+93,476
| +15% | +$762K | ﹤0.01% | 1829 |
|
|
2015
Q2 | $5.43M | Sell |
613,628
-289,346
| -32% | -$2.74M | ﹤0.01% | 1745 |
|
|
2015
Q1 | $8.9M | Buy |
902,974
+475,353
| +111% | +$5.94M | 0.01% | 1421 |
|
|
2014
Q4 | $5.24M | Buy |
427,621
+79,954
| +23% | +$976K | ﹤0.01% | 1921 |
|
|
2014
Q3 | $3.47M | Buy |
347,667
+118,117
| +51% | +$1.1M | ﹤0.01% | 2096 |
|
|
2014
Q2 | $1.74M | Sell |
229,550
-289,602
| -56% | -$1.16M | ﹤0.01% | 2536 |
|
|
2014
Q1 | $1.71M | Buy |
519,152
+202,409
| +64% | +$708K | ﹤0.01% | 2504 |
|
|
2013
Q4 | $1.05M | Buy |
316,743
+76,087
| +32% | +$221K | ﹤0.01% | 2628 |
|
|
2013
Q3 | $725K | Buy |
240,656
+52,655
| +28% | +$361K | ﹤0.01% | 3221 |
|
|
2013
Q2 | $1.53M | Buy |
+188,001
| New | +$1.44M | ﹤0.01% | 2390 |
|
Deutsche Bank's ACHN Position: Q1 2020 in Review
Deutsche Bank sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 45,651 shares — an estimated $275K sold.
Deutsche Bank first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $15.3M in Q4 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Deutsche Bank reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Deutsche Bank sold 45,651 Achillion Pharmaceuticals shares in Q1 2020, an estimated $275K.
- Deutsche Bank first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Deutsche Bank's Achillion Pharmaceuticals position peaked at $15.3M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Deutsche Bank's 13F filing for Q1 2020, filed 14 May 2020.